Additional information
| Weight | 0.94 oz |
|---|---|
| Strength | 5mg, 10mg, 20mg, 30mg, 40mg, 60mg |
GLP-1C
$50.40 – $92.40Price range: $50.40 through $92.40 SAVE 30%
GLP-1S
$47.20 – $79.20Price range: $47.20 through $79.20 SAVE 20%
$41.60 – $174.25Price range: $41.60 through $174.25 SAVE 20–33%
-33%Dual-receptor agonist activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism engages two distinct incretin pathways simultaneously — an approach that has generated significant clinical research interest. Research areas include body weight regulation, glycemic control through dual incretin signaling, cardiovascular metabolic effects, and comparative studies with single-receptor agonists. For research use only — not for human consumption.
GLP-1T is currently a mixed-batch product. The 20mg, 30mg, and 60mg strengths are from Batch 2 and are in Janoshik testing now.
Due to recent supply chain and international shipping disruptions, some Batch 002 inventory may include vials produced at different points within our supplier’s production cycle. As a result, researchers may notice minor packaging variations, including differences in vial caps.
These products were sourced from the same established manufacturers we have worked with for ongoing quality and third-party testing. That said, we want to be transparent that Batch 002 may not represent a single uninterrupted production run.
We are already working with our suppliers to strengthen batch-control, packaging, and documentation protocols before Batch 003.
| Weight | 0.94 oz |
|---|---|
| Strength | 5mg, 10mg, 20mg, 30mg, 40mg, 60mg |
Metabolic Research, Research Bundles
Due to recent supply chain and international shipping disruptions, some Batch 002 inventory may include vials produced at different points within our supplier’s production cycle. As a result, researchers may notice minor packaging variations, including differences in vial caps.
These products were sourced from the same established manufacturers we have worked with for ongoing quality and third-party testing. That said, we want to be transparent that Batch 002 may not represent a single uninterrupted production run.
We are already working with our suppliers to strengthen batch-control, packaging, and documentation protocols before Batch 003.
